Seminars in Oncology
Volume 36, Issue 4 , Pages 312-323, August 2009

Translocation-Related SarcomasDisclosures

  • Fredrik Mertens

      Affiliations

    • Department of Clinical Genetics, Lund University Hospital, Lund, Sweden
    • These authors contributed equally to this work.
  • ,
  • Cristina R. Antonescu

      Affiliations

    • Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • These authors contributed equally to this work.
  • ,
  • Peter Hohenberger

      Affiliations

    • Division of Surgical Oncology and Thoracic Surgery, Department of Surgery, University Hospital Mannheim, Mannheim, Germany
    • These authors contributed equally to this work.
  • ,
  • Marc Ladanyi

      Affiliations

    • Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • These authors contributed equally to this work.
  • ,
  • Piergiorgio Modena

      Affiliations

    • Unit of Molecular Cytogenetics, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
    • These authors contributed equally to this work.
  • ,
  • Maurizio D'Incalci

      Affiliations

    • Department of Oncology, Mario Negri Institute, Milan, Italy
    • These authors contributed equally to this work.
  • ,
  • Paolo G. Casali

      Affiliations

    • Istituto Nazionale Tumori, Milan, Italy
    • These authors contributed equally to this work.
  • ,
  • Massimo Aglietta

      Affiliations

    • University of Torino-Ospedale Mauriziano, IRCC, Candiolo, Italy
    • These authors contributed equally to this work.
  • ,
  • Thor Alvegård

      Affiliations

    • Department of Cancer Epidemiology, University Hospital, Lund, Sweden
    • These authors contributed equally to this work.
    • Corresponding Author InformationAddress correspondence to Thor Alvegård, MD, PhD, University Hospital, Department of Cancer Epidemiology, Lund S-221-85, Sweden

Sarcomas with chromosomal translocations represent only about one fourth of sarcoma diagnoses. However, like gastrointestinal stromal tumor (GIST), with its characteristic KIT or PDGFRA mutations, they are particularly interesting since they provide specific biological insights and mechanisms of action that may have an impact upon prognosis or therapy. These are mechanisms we are just beginning to exploit. In this section we will review the biology and clinical impact of translocation-associated sarcomas and review the clinical findings that have made a recent impact upon patients with these diverse diagnoses.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

Disclosures Paolo G. Casali: Pharma Mar, Johnson & Johnson (research funds), Pharma Mar (honoraria); Maurizio D'Incalci: Pharma Mar (research funds).Other authors: none

PII: S0093-7754(09)00104-3

doi:10.1053/j.seminoncol.2009.06.004

Seminars in Oncology
Volume 36, Issue 4 , Pages 312-323, August 2009